MTOR and urinary bladder carcinoma: Then, SC79 (activator of AKT) was used to treat bladder cancer cells transfected with UCHL5 shRNA, and Western blotting analysis showed rescue of p-AKT/p-mTOR protein expression affected by UCHL5 knockdown.